Jit Basak
President, CEO

Jit Basak is the President and CEO of Catailyst Inc. Previously, he was a Transaction Lead of Corporate Development at Shire/Takeda; Inotek Pharmaceutical following Investment Banking Advisory roles. He was a FINRA-registered investment banker and has led transactional work with increasing responsibilities at Ferghana Partners and Capstone-Headwaters. Earlier in his career, Jit spent nine years as a medicinal chemist in multiple therapeutic areas at both midsize biotech and large pharmaceutical companies: Chemocentryx, Inc. and Pfizer, Inc. After completing his post-doctoral research at University of Chicago, he received his MBA from the University of Connecticut School of Business in finance and international business. Jit holds a PhD degree from University Illinois at Chicago in synthetic organic chemistry and master’s degree in chemistry from Indian Institute of Technology Kanpur, India.

Sandipan Chattopadhyay
Chief Technology Officer

Sandipan Chattopadhyay, aged 49 years, is the Managing Director and Chief Executive Officer of Xelpmoc. He holds a degree of Bachelor of Statistics (Honors) from the Indian Statistical Institute, Calcutta. He also holds a Post Graduate Diploma in Computer Aided Management from the Indian Institute of Management, Kolkata.

He is primarily responsible for the performance and supervision of technical, administrative and day-to-day operations of , including but not limited to developing strategic plans, promotion of revenue, profitability and growth of Xelpmoc. He has more than 24 years of experience in the field of technology. Prior to joining Xelpmoc, he has served as the Chief Technical Officer at Just Dial Limited. He has been a Director on Xelpmoc Board since incorporation.

Steve Gullans, Ph.D.
Board Member

Steve Gullans, Ph.D., is an experienced executive, venture investor, entrepreneur, educator, and author. He has served as CEO and board director of more than a dozen private and public companies. He advises companies regarding strategy, financings, commercialization and governance.

Steve is currently co-founder and CEO of digital health company named Thynk, Inc. and he previously served as CEO of Gemphire Therapeutics, Inc. As a venture investor he was co-founder and Managing Director at Excel Venture Management (EVM), a firm he co-founded that has $225M invested across more than 40 companies. Steve is currently a board director at Orionis Biosciences, iSpecimen, Thynk, Navigation Sciences, and Alexis Bio. He began his career as a professor at Harvard Medical School after earning his Ph.D. from Duke University and post-doctoral training at Yale University. He has co-authored more than 130 scientific papers and was elected a Fellow of the AAAS and AHA.